{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-21-034761","form_type":"8-K","ticker":"ADMA","cik":"0001368514","company_name":"ADMA BIOLOGICS, INC.","filed_at":"2021-10-18T23:59:59+00:00","discovered_at":"2026-05-14T18:04:12.261036+00:00","generated_at":"2026-06-28T20:14:26.042326+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"ADMA Biologics adds former Momenta CFO/CO Young T. Kwon to Board","bullets":["Dr. Kwon appointed as Class II director with term through 2024 annual meeting.","Previously served as CFO/CO at Momenta, leading its $6.5B sale to Johnson & Johnson in 2020.","Will receive an initial grant of options to purchase 93,500 shares of common stock.","Currently an operating partner at Lightstone Ventures, assisting with deal sourcing and portfolio management.","Brings over a decade of strategic, financial, and business development experience in biotech."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-21-034761","json":"https://secwatch.observer/filing/0001140361-21-034761.json","markdown":"https://secwatch.observer/filing/0001140361-21-034761.md","text":"https://secwatch.observer/filing/0001140361-21-034761.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1368514/000114036121034761/0001140361-21-034761-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1368514/000114036121034761/brhc10029850_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T20:14:26.042326+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9a3f8953ff","claim":"Young T. Kwon was appointed as Class II director at ADMA BIOLOGICS, INC..","evidence_excerpt":"On October 15, 2021, the Board of Directors (the “Board”) of ADMA Biologics, Inc. (the “Company”) appointed Young T. Kwon, Ph.D. to serve on the Board as a Class II director with a term expiring at the Company’s 2024 annual meeting of stockholders.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1368514/000114036121034761/0001140361-21-034761-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class II director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}